Roos Van Elzen

Roos Van Elzen

Auto-generated profile, based on publicly available information

Roos Van Elzen

CellCarta, Antwerp, Belgium

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2025 in Cancer Immunology Research
Verified
Journal Article
Open access
MGMatthew D. Galsky
Matthew D. Galsky
MKMark Kockx
Mark Kockx
JRJuliette Roels
Juliette Roels
RERoos Van Elzen
Roos Van Elzen
XGXiangnan Guan
Xiangnan Guan
SMSanjeev Mariathasan
Sanjeev Mariathasan
Testing for PD-L1 expression by IHC is used to predict immune checkpoint blockade (ICB) benefits but has performed inconsistently in urothelial cancer clinical trials. Different approaches are used for PD-L1 IHC. We analyzed paired PD-L1 IHC data on urothelial cancer samples using the SP142 and 22C3 assays from the phase III IMvigor130 trial and found discordant findings summarized by four phenotypes: PD-L1 positive by both assays, PD-L1 positive by the SP142 assay only, PD-L1 positive by the 22C3 assay only, and PD-L1 negative by both assays double negative. PD-L1 positive by both assays and PD-L1 positive by the SP142 assay only urothelial cancers were associated with more favorable ICB outcomes and increased dendritic cell (DC) infiltration. SP142 PD-L1 staining co-localized with DC-LAMP, a DC marker, whereas 22C3 staining was more diffuse. PD-L1 positive by the 22C3 assay only urothelial cancers, associated with worse outcomes, were enriched in tumor cell (TC)–dominant PD-L1 expression. Multiplex IHC in an independent ICB-treated cohort confirmed that TC-dominant PD-L1 expression was associated with shorter survival. Using different PD-L1 assays, we uncovered that SP142 may preferentially stain PD-L1–expressing DCs, key to orchestrating antitumor immunity, whereas TC-dominant PD-L1 expression, which underlies a subset of “PD-L1–positive” specimens, is associated with poor ICB outcomes. See related Spotlight by Karunamurthy and Davar, p. 454 .

11 December 2009 in Journal of Proteome Research
Verified
Journal Article
Closed access
RERoos Van Elzen
Roos Van Elzen
Bart GhesquiereBart Ghesquiere
Bart Ghesquiere
ETEvy Timmerman
Evy Timmerman
SVStefaan Vandamme
Stefaan Vandamme
LMLuc Moens
Luc Moens
SDSylvia Dewilde
Sylvia Dewilde

24 May 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
RERoos Van Elzen
Roos Van Elzen
AKAlbert Konijnenberg
Albert Konijnenberg
PVPieter Van Der Veken
Pieter Van Der Veken
MEMatthew J. Edgeworth
Matthew J. Edgeworth
JSJames H. Scrivens
James H. Scrivens
ALAnne-Marie Lambeir
Anne-Marie Lambeir
Ion mobility mass spectrometry (IM-MS) can be used to analyze native proteins according to their size and shape. By sampling individual molecules, it allows us to study mixtures of conformations, as long as they have different collision cross sections and maintain their native conformation after dehydration and vaporization in the mass spectrometer. Even though conformational heterogeneity of prolyl oligopeptidase has been demonstrated in solution, it is not detectable in IM-MS. Factors that affect the conformation in solution, binding of an active site ligand, the stabilizing Ser554Ala mutation, and acidification do not qualitatively affect the collision-induced unfolding pattern. However, measuring the protection of accessible cysteines upon ligand binding provides a principle for the development of MS-based ligand screening methods.